NORDEA BANK FINLAND PLC'S MARKET-MAKING FOR BIOTIE THERAPIES CORP.'S SHARE ENDS

(Thomson Reuters ONE) -


BIOTIE THERAPIES CORP.                STOCK EXCHANGE RELEASE    18 May 2016, at
6.20 p.m. (EET)



NORDEA BANK FINLAND PLC'S MARKET-MAKING FOR BIOTIE THERAPIES CORP.'S SHARE ENDS

Biotie Therapies Corp. ("Biotie") and Nordea Bank Finland Plc ("Nordea") have
jointly agreed to terminate the market-making agreement entered into between
Biotie and Nordea on 21 September 2009. The market-making ends on 20 June 2016.

Turku, 18 May 2016

Biotie Therapies Corp.
Timo Veromaa
President and CEO

For further information, please contact:
Virve Nurmi, Biotie Therapies Corp.
tel. +358 2 274 8900, e-mail: virve.nurmi(at)biotie.com

DISTRIBUTION:
www.biotie.com
Nasdaq Helsinki Ltd
Main Media

INFORMATION REGARDING BIOTIE

Biotie is a biopharmaceutical company focused on products for neurodegenerative
and psychiatric disorders. Biotie's development has delivered Selincro
(nalmefene) for alcohol dependence, which received European marketing
authorization in 2013 and is currently being marketed across Europe by partner
Lundbeck. The current development products include tozadenant for Parkinson's
disease, which is in Phase 3 development, and two additional compounds which are
in Phase 2 development for cognitive disorders including Parkinson's disease
dementia, and primary sclerosing cholangitis (PSC), a rare fibrotic disease of
the liver.




This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Biotie Therapies Oyj via GlobeNewswire

[HUG#2013694]

Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 18.05.2016 - 17:20 Uhr
Sprache: Deutsch
News-ID 472099
Anzahl Zeichen: 2121

contact information:
Town:

Turku

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 292 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"NORDEA BANK FINLAND PLC'S MARKET-MAKING FOR BIOTIE THERAPIES CORP.'S SHARE ENDS"
steht unter der journalistisch-redaktionellen Verantwortung von

Biotie Therapies Oyj (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Biotie Announces Start of Clinical Study With Nepicastat (SYN117) in Cocaine Dep ...

TURKU, FINLAND -- (Marketwired) -- 05/10/13 -- BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 10 May 2013 at 9.00 a.m.Biotie Therapies today announced the start of a Phase 2 clinical study evaluating nepicastat (SYN117) in cocaine dependence. The Nat ...

Biotie: Selincro Launched in the United Kingdom ...

TURKU, FINLAND -- (Marketwired) -- 05/06/13 -- Biotie today announced that its partner H.Lundbeck A/S (Lundbeck) has launched Selincro in the United Kingdom. According to the terms of the license agreement between Biotie and Lundbeck for Selincro, B ...

Biotie: Selincro Launched in First European Markets ...

TURKU, FINLAND -- (Marketwired) -- 04/22/13 -- BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 22 April 2013 at 9:00 a.m.Biotie today announced that its partner H.Lundbeck A/S (Lundbeck) has started launching Selincro™ in the first European markets, ...

Alle Meldungen von Biotie Therapies Oyj